SUBSCRIBE
SUBSCRIBE
News   Drug Development

Cancer Prevention Pharmaceuticals Receives Positive Scientific Advice From EMA for CPP-1X Phase III TRIAL in FAP

July 29, 2011 | 
1 min read
TUCSON, Ariz., July 29, 2011 (GLOBE NEWSWIRE) -- Cancer Prevention Pharmaceuticals, Inc. (CPP) has received positive advice from the European Medicines Agency (EMA) regarding its Phase III trial in Familial Adenomatous Polyposis (FAP).
Clinical research Phase 3
MORE ON THIS TOPIC
Abstract creative art collage, market declines in the stock market. The concept of collapse or bankruptcy.
Cancer
Karyopharm Slides as Mixed Myelofibrosis Results Cloud Regulatory Road
March 25, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
March 25, 2026
 · 
1 min read
 · 
Heather McKenzie
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Obesity
Aardvark Pauses 2 Obesity Trials, Reveals New Details on Cardiac Concerns
March 24, 2026
 · 
2 min read
 · 
Tristan Manalac
Checklist collage banner with halftone hands. Hand holding marker and putting a check mark or cross in checkbox. Collage design with halftone elements. Concept of check list. Vector illustration.
Vaccines
Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint
March 23, 2026
 · 
2 min read
 · 
Heather McKenzie